These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32355214)

  • 1. Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity.
    Zebertavage LK; Alice A; Crittenden MR; Gough MJ
    Sci Rep; 2020 Apr; 10(1):7376. PubMed ID: 32355214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
    Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
    Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
    Accolla RS; Ramia E; Tedeschi A; Forlani G
    Front Immunol; 2019; 10():1806. PubMed ID: 31417570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
    Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
    Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity.
    Peng L; Zhou L; Li H; Zhang X; Li S; Wang K; Yang M; Ma X; Zhang D; Xiang S; Duan Y; Wang T; Sun C; Wang C; Lu D; Qian M; Wang Z
    Cell Rep; 2024 Apr; 43(4):114003. PubMed ID: 38527062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
    van Montfoort N; Borst L; Korrer MJ; Sluijter M; Marijt KA; Santegoets SJ; van Ham VJ; Ehsan I; Charoentong P; André P; Wagtmann N; Welters MJP; Kim YJ; Piersma SJ; van der Burg SH; van Hall T
    Cell; 2018 Dec; 175(7):1744-1755.e15. PubMed ID: 30503208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8
    Lupfer CR; Stokes KL; Kuriakose T; Kanneganti TD
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.
    Chen J; Cao Y; Markelc B; Kaeppler J; Vermeer JA; Muschel RJ
    J Clin Invest; 2019 Oct; 129(10):4224-4238. PubMed ID: 31483286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
    Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
    J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
    Xu H; Van der Jeught K; Zhou Z; Zhang L; Yu T; Sun Y; Li Y; Wan C; So KM; Liu D; Frieden M; Fang Y; Mosley AL; He X; Zhang X; Sandusky GE; Liu Y; Meroueh SO; Zhang C; Wijeratne AB; Huang C; Ji G; Lu X
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33830945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
    Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
    Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photothermally Controlled MHC Class I Restricted CD8
    Cao F; Yan M; Liu Y; Liu L; Ma G
    Adv Healthc Mater; 2018 May; 7(10):e1701439. PubMed ID: 29508543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A STING-activating nanovaccine for cancer immunotherapy.
    Luo M; Wang H; Wang Z; Cai H; Lu Z; Li Y; Du M; Huang G; Wang C; Chen X; Porembka MR; Lea J; Frankel AE; Fu YX; Chen ZJ; Gao J
    Nat Nanotechnol; 2017 Jul; 12(7):648-654. PubMed ID: 28436963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
    Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
    J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.
    Yao Y; Wang Y; Chen F; Huang Y; Zhu S; Leng Q; Wang H; Shi Y; Qian Y
    Cell Res; 2012 May; 22(5):836-47. PubMed ID: 22491475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.